MarketScreener Strategies Vertex Pharmaceuticals Incorporated
Stocks
VRTX
US92532F1003
Pharmaceuticals
|
Market Closed -
Nasdaq
16:00:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 505.75 USD | -2.07% |
|
+1.95% | +11.56% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
MarketScreener Strategies
Search
 | Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease | December 11, 2023 at 05:47 am |
 | Vertex Pharmaceuticals Incorporated : Confirms growth trajectory | May 04, 2023 at 09:35 am |
 | Vertex Pharmaceuticals : A very promising pipeline | January 11, 2023 at 05:20 am |
No results match your criteria
- Stock Market
- Stocks
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
